Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Enhanced type I interferon gene signature in primary antiphospholipid syndrome: Association with earlier disease onset and preeclampsia

Full text
Author(s):
Ugolini-Lopes, Michelle Remiao [1] ; Torrezan, Giovana Tardin [2] ; Rossi Gandara, Ana Paula [1] ; Ribeiro Olivieri, Eloisa Helena [2] ; Nascimento, Iana Souza [1] ; Okazaki, Erica [3] ; Bonfa, Eloisa [1] ; Carraro, Dirce Maria [2] ; Oliveira de Andrade, Danieli Castro [1]
Total Authors: 9
Affiliation:
[1] Univ Sao Paulo, Fac Med, Rheumatol Div, Sao Paulo - Brazil
[2] AC Camargo Canc Ctr, Lab Genom & Mol Biol, Sao Paulo - Brazil
[3] Univ Sao Paulo, Fac Med, Hematol Div, Sao Paulo - Brazil
Total Affiliations: 3
Document type: Review article
Source: AUTOIMMUNITY REVIEWS; v. 18, n. 4, p. 393-398, APR 2019.
Web of Science Citations: 3
Abstract

Objective: Recently, two studies demonstrated that a relevant percentage of primary antiphospholipid syndrome (PAPS) patients had an upregulation of interferon (IFN) genes. However, 20%-28% of these patients had anti-dsDNA, a highly specific systemic lupus erythematosus (SLE) autoantibody. This study aimed to determine the prevalence of the type I IFN signature in the peripheral blood mononuclear cells of PAPS patients without specific SLE autoantibodies and search for its clinical associations. Methods: Fifty-three PAPS patients (Sydney's criteria) were consecutively selected and age-matched with 50 healthy controls. A third group of nonimmune-mediated thrombophilia patients was also included. The expression of 41 IFN-induced genes was analyzed using real time quantitative PCR. A principal component analysis determined which genes composed the IFN signature, and the z-score was calculated. An ROC curve defined the signature cut-off. Results: Six genes remained in the IFN signature DNAJA1, IFIT5, IF127, MX1, IF16, and TYK2. The ROC cutoff was 3.9-fold (AUC = 0.706, S = 0.49, E = 0.86, PPV = 0.79, NPV = 0.61). The type I IFN signature was present in 49% of the patients with PAPS compared with 14.0% of the healthy controls and 17% of the nonimmunemediated thrombophilia patients (p < .0001). The IFN signature was associated with a younger age at the first antiphospholipid syndrome event (p = .023) and with preeclampsia (p = .032). Conclusion: Our results indicate that PAPS patients without lupus-specific antibodies have an enhanced type IFN gene signature that is not observed in nonimmune-mediated thrombophilia. Also, this overexpression of type I IFN-regulated genes associated with an earlier onset of antiphospholipid syndrome event and preeclampsia. (AU)

FAPESP's process: 14/17965-1 - Type I Interferon Signature in Primary Antiphospholipid Syndrome
Grantee:Danieli Castro Oliveira de Andrade
Support type: Regular Research Grants